Articles tagged with Hepatitis C
Researchers found that a hepatitis C virus protein accelerates the breakdown of a critical tumor suppressor, leading to liver cell proliferation and increasing cancer risk. This discovery could lead to improved treatment strategies for patients with chronic hepatitis C.
Research reveals that patients with Hepatitis C are using more healthcare resources, including increased hospitalizations, physician visits, and costs due to disease progression. The study highlights the urgent need for better HCV treatment decisions as the patient population ages.
A new study by Regino González-Peralta and colleagues found that interferon in combination with ribavirin is an effective treatment for childhood chronic hepatitis C, with sustained virologic response rates higher than those using interferon alone. Common side effects were mild, but severe adverse events occurred in some children.
Research by Chuan-Qing Wang and colleagues found that morphine withdrawal and precipitated withdrawal increase HCV replicon expression and inhibit IFN-alpha production in liver cells. This study suggests that opioid abuse may contribute to the chronicity of HCV infection and promote disease progression.
A new study finds that co-therapy with erythropoietin is more cost-effective than standard treatment for patients with Hepatitis C and treatment-induced anemia. The research suggests that this treatment approach can improve rates of complete cure from the disease, making it a viable option for this patient population.
A recent study published by the American Gastroenterological Association found that nearly 80% of Asian patients with chronic HCV developed cirrhosis after 60 years of infection. The study's results confirm that fibrosis progression is the same across ethnic groups, leading to cirrhosis and liver disease at a similar rate in everyone.
Researchers identify genetic changes in hepatitis C virus that evade immune system, leading to chronic infections. The findings suggest a 'consensus sequence' could serve as basis for effective vaccines against both acute and chronic infections.
A steroid-free regimen with CellCept was found to be comparable to standard therapy in liver transplantation, without increasing the risk of hepatitis C recurrence. The study involved 312 adult patients and showed that the CellCept-based regimen demonstrated comparable efficacy and safety profiles.
A new study found that peginterferon-alfa-2b with ribavirin was well-tolerated and yielded a sustained viral response in 59% of children with chronic hepatitis C. Patients infected via needle or with normal liver enzyme levels responded better to treatment.
The first UK cases of Lymphogranuloma venereum (LGV) have been reported in gay men, mostly from London. The disease is caused by a particularly invasive strain of Chlamydia trachomatis and can lead to chronic infection with fistulas and problems with the lymphatic system.
A systematic review found that Hepatitis C significantly impacts quality of life, affecting physical and social function, general health and vitality. Researchers established a minimally clinically important difference in vitality scale to monitor patient outcomes.
A study of liver transplant patients with hepatitis C found that donor age does not impact long-term survival rates. Instead, maintenance azathioprine was associated with improved overall and 3-month survival rates, suggesting a complex relationship between immunosuppression and disease progression.
Researchers discover how hepatitis C virus (HCV) replicates unchecked despite the presence of immune defenses triggered by the RIG-I protein. HCV produces a viral protease that disrupts the signaling pathway, allowing it to continue replication. Protease inhibitors show promise in treating HCV and possibly other viral infections
A recent study by Emory University Health Sciences Center found that patients with depression are less likely to clear the hepatitis C virus from their blood after six months of treatment. Only 34% of those experiencing a significant increase in depression were able to clear the virus, compared to 59-69% of those with milder increases
Researchers demonstrate that long-term maintenance therapy with peginterferon alfa-2b can prevent or delay the progression of hepatitis C, reducing the risk of liver damage by half. A new antiviral agent, NM283, also shows promising activity against genotype 1 HCV, offering hope for future therapies.
A study of nearly 400 African-American patients found that weight-based REBETOL dosing with PEG-INTRON improved viral clearance and reduced relapse rates compared to a flat dose. The treatment showed promise in improving outcomes for this patient population, which has historically had lower response rates to hepatitis C therapy.
A new study finds that combining Pegasys with ribavirin reduces hepatitis C viral levels more effectively than Peg-Intron, a promising development in treating the virus. The study's lead investigator hopes that the findings will inform the design of better drugs to combat the infection.
Research in British Columbia found a seventeen-fold higher risk of diffuse large B-Cell lymphoma in HCV-infected patients. The study confirmed the viral-cancer link, previously suspected in studies from other regions with higher hepatitis C prevalence.
A study found that patients who received liver transplants from living donors are more likely to experience severe Hepatitis C recurrence. The research, led by Xavier Forns, investigated the effect of donor life status on HCV patient outcomes and discovered a significant association between living donor transplantation and severe disea...
Research on hepatitis C patients after liver transplantation found that 10-year outcomes are similar to those for other indications, but risk of recurrence and failure increases over time. Factors such as donor and recipient age, viral load, and CMV antibodies can predict transplant success.
A study found that genetic characteristics in patients who self-recovered from hepatitis C infection involve genes that suppress the action of killer immune cells. Researchers hope to develop a vaccine and improve therapies based on these findings.
A groundbreaking study by Mount Sinai School of Medicine found that the combination of Pegasysα and Copegus significantly improved treatment response rates for patients co-infected with HCV and HIV. The study showed a sustained virological response rate of 40% among all patients, with even higher efficacy rates for those with genotypes...
Researchers at Yale University have made significant breakthroughs in understanding the helicase function of the hepatitis C virus. By visualizing the behavior of the viral enzyme NS3, scientists discovered that it moves with a discontinuous stepping motion that alternates rapid translocation with pausing.
A study led by Duke University Medical Center researchers found African-Americans have a significantly lower response rate to treatment for chronic hepatitis C. Only 19% of African-American patients responded to the drug combination, while 52% of non-Hispanic white patients achieved a sustained virologic response.
A study of 299 smokers found that nicotine nasal spray and skin patch both led to similar abstinence rates after six months. However, certain groups achieved higher success rates with one form over the other based on their ethnic background, weight and nicotine dependence level.
A multinational trial found that the combination of Pegasys and Copegus significantly increased sustained virological response rates in patients co-infected with HIV and Hepatitis C. The study reported 40% overall efficacy, including 62% efficacy for genotype 2 and 3 patients.
A new investigational vaccine to prevent hepatitis C has been tested in humans for the first time, offering a promising breakthrough against the deadly virus. The study aimed to assess the safety and effectiveness of three different strengths of the Chiron Corporation's vaccine.
A study of HIV-infected patients undergoing liver transplantation found improved survival rates compared to HIV-negative patients. Poorer survival was associated with postoperative intolerance, low CD4 counts, and hepatitis C coinfection.
A triple therapy study using ZADAXIN in combination with pegylated interferon alpha and ribavirin showed a 61% response rate for patients with hepatitis C who were non-responders to previous treatment. The study found that ZADAXIN improved response rates for these patients.
A new clinical trial led by Duke University aims to compare the efficacy of two pegylated interferon treatments for hepatitis C virus. The IDEAL trial will enroll 2,880 patients and determine which treatment results in a sustained viral response in the largest proportion of patients.
A new study found that alcohol consumption increases the activity of a protein that causes the hepatitis C virus to replicate, leading to liver disease. The study also discovered that alcohol interferes with antiviral treatment, such as interferon-alpha, which is currently the only licensed treatment for the infection.
Researchers identify viral protease NS3/4A as a key player in evading the immune system, leading to new avenues for clinical and basic research on hepatitis C. Inhibiting this protease restores the host's immune response, reducing viral levels to nearly undetectable levels.
Researchers discovered that a new class of protease inhibitors can prevent the hepatitis C virus from blocking the innate immune response, restoring it in human cells. This finding suggests that these drugs will have dual efficacy and could become an important addition to existing treatments for hepatitis C.
A new study has established genetic associations in hepatitis C, finding correlations between the CD4 and IL-1B genes and disease activity. The research suggests a possible role of intrahepatic CD4 T cells in hepatic injury and immune response to HCV infection.
The University of Washington has established a $9 million center to study the underlying causes of hepatitis-induced liver disease. The center brings together experts in viral hepatitis, liver disease, and transplantation to investigate gene and protein expression in liver cells.
A study of 39 hepatitis C patients found that 33% developed interferon-induced major depression, but 84% improved with antidepressant treatment. The research challenges the common practice of discontinuing interferon therapy for depressed patients.
A new study found that a combination of peginterferon alfa-2a and ribavirin can offer superior efficacy without increasing common side effects, particularly in patients infected with hepatitis C genotype 1. The treatment approach showed a higher sustained response rate compared to standard therapy.
A recent study by Mayo Clinic researchers found that patients with alcoholic-liver disease are at a higher risk of developing confusion and delirium after liver transplant surgery. The study, which included 87 patients, revealed that the length of sobriety before surgery is directly correlated to the severity of these complications.
Scientists followed nearly 2,000 HIV-infected patients with varying levels of hepatitis C exposure. They found that exposure to hepatitis C did not increase risk of death or AIDS progression but was associated with lower antiretroviral therapy prescriptions, which may lead to increased mortality rates in this group.
A Johns Hopkins Medicine study reveals that HIV treatment is equally effective for patients with both HIV and hepatitis C infections, contrary to previous assumptions. The research found no significant difference in the virologic or immunologic response to HAART among those with co-infection, suggesting hepatitis C infection should not...
The consensus panel recommends expanding hepatitis C treatment to include patients who use injected drugs, suffer from co-morbid conditions, or are coinfected with HIV. Reliable HCV cultures and research networks are also prioritized to advance understanding of the disease and develop new treatments.
The VIRAHEP-C clinical trial investigates the effectiveness of combination therapy for chronic hepatitis C, with a focus on racial disparities. Researchers hope to determine factors associated with sustained virological response rates in African-American patients, who are disproportionately affected by the disease.
Researchers found that humans can acquire immunity to hepatitis C virus, reducing the risk of persistent infection and its complications like liver cirrhosis and cancer. The study's findings add to growing evidence that vaccines could be used to protect against hepatitis C.
A combination treatment of Pegasys and ribavirin has shown an unprecedented 61% sustained virologic response rate, the highest ever recorded. The treatment regimen should be based on hepatitis C virus genotype rather than traditional weight-based methodology.
A UCSF study found high levels of HCV infection among young low-income women in San Francisco, with injection drug use and HSV-2 co-infection contributing to transmission. The study also highlights the need for public health efforts beyond needle exchange programs to address non-needle drug use and sexually transmitted diseases.
A study found that 81.6% of injection drug users in Vancouver had hepatitis C antibodies, with 62 new cases reported among those initially negative. Risk factors for infection included female sex, cocaine use, and frequent needle-exchange program attendance.
A new combination drug treatment has shown to be more effective in treating chronic hepatitis C than the current standard. The treatment, peginterferon alfa-2b plus ribavirin, achieved higher sustained viral response rates compared to interferon alfa-2b plus ribavirin, especially in patients with genotype 1 infection.
Researchers have developed a mouse model that can be infected with the hepatitis C virus, allowing them to test new therapies and study viral replication. This breakthrough could lead to the development of a cure for the disease, which affects an estimated 175 million people worldwide.
Researchers in Canada are developing a class of drugs for chronic pain with fewer side effects. Canadian scientists also presenting promising treatments for Hepatitis C and non-insulin dependent diabetes by targeting key enzymes involved in the diseases.
A recent study from the University of California, San Francisco has discovered a novel mechanism by which the drug ribavirin kills viruses by generating excess mutations that overwhelm the virus. This unexpected finding may lead to the development of more effective anti-viral treatments for hepatitis C patients.
Researchers found a way to grow hepatitis C virus in labs, enabling genetic studies and potential vaccine development. The breakthrough could speed up progress against the disease, which affects 170 million worldwide.
Researchers identify gC1qR as a binding partner for Hepatitis C core protein, allowing the virus to evade immune response and persist in the body. The interaction between gC1qR and core protein may provide new targets for developing therapies to combat chronic hepatitis C.
A study led by the National Institutes of Health (NIH) has identified key changes in surface proteins of the hepatitis C virus (HCV) that enable it to evade the immune system. The research found that these changes occur early in the infection process and can determine whether a person will develop chronic or acute HCV disease.
A University of Maryland School of Medicine study found that mass treatment campaigns for schistosomiasis in Egypt led to a significant transmission of hepatitis C. The campaign used reusable needles and syringes, which were later replaced with disposable ones.
Researchers at Chiron Corporation have identified a protein molecule (CD81) that binds to the hepatitis C virus (HCV), providing clues on how the virus infects human cells. This discovery has significant implications for the development of new vaccines and therapeutics to prevent and treat chronic HCV infection.
A collaborative study between the US and Russia aims to uncover the causes of Hepatitis C, a prevalent liver disease. The project will collect blood samples and questionnaires from over 4,000 individuals across New Mexico and Chelyabinsk-70, with results expected to shed new light on the virus.
Researchers at the University of Washington have discovered a potential new target for therapeutic drugs to treat hepatitis C. The study found that a protein called NS5A can bind to and inactivate a key component of interferon response, PKR. This could lead to the development of a new treatment for the disease.